Somatic Care with a Psychotic Disorder. Lower Somatic Health Care Utilization of Patients with a Psychotic Disorder Compared to Other Patient Groups and to Controls Without a Psychiatric Diagnosis by unknown
ORIGINAL ARTICLE
Somatic Care with a Psychotic Disorder. Lower Somatic Health
Care Utilization of Patients with a Psychotic Disorder Compared
to Other Patient Groups and to Controls Without a Psychiatric
Diagnosis
Wilma Swildens1 • Fabian Termorshuizen2,3 • Alex de Ridder4 • Hugo Smeets2,5 •
Iris M. Engelhard1,6
Published online: 28 September 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Patients with non-affective psychotic disorders
(NAPD) face higher risk of somatic problems and early
natural death compared to the general population. There-
fore, treatment guidelines for schizophrenia and psychosis
stress the importance of monitoring somatic risk factors.
This study examined somatic Health Care utilization (HCu)
of patients with NAPD compared to non-psychiatric con-
trols and patients with depression, anxiety or bipolar dis-
orders using a large Health Insurance database. Results
show lower specialist somatic HCu of patients with NAPD
compared to matched controls and also lower percentages
for prescribed somatic medication and general practitioner
consultations for patients aged C60 years and after longer
illness duration.
Keywords Mental health  Schizophrenia  Somatic
Health Care utilization
Introduction
An increasing body of evidence suggests that patients with
non-affective psychotic disorder (NAPD), which involves
schizophrenia, schizophreniform disorder, schizoaffective
disorder, delusional disorder and psychosis not otherwise
specified (Kendler et al. 1996; Kessler et al. 2005) have
somatic problems in need of clinical attention. They have a
higher risk of physical disorders and a mean life expec-
tancy that is at least 15 years shorter compared to the
general population (Altamura et al. 2011; Carney et al.
2006; De Hert et al. 2011a; Wahlbeck et al. 2011; Weber
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et al. 2009). Premature mortality is strongly associated with
natural death causes and the increased relative risk of
natural death is already present at a relatively young
age (Hennekens et al. 2005; Capasso et al. 2008;
Termorshuizen et al. 2013). Associated causes include
higher somatic disease incidence (often cardiovascular and
respiratory diseases), but a lower quality of somatic health
care, underdiagnosis and undertreatment (Bradford et al.
2008; De Hert et al. 2011a; Mitchell et al. 2009; Nasrallah
et al. 2006; Laursen et al. 2011). Patients with severe mental
illness (SMI) also report more difficulties in accessing care
than the general population (Bradford et al. 2008).
Given the poor health condition of patients and
increased risk of natural death causes (Laursen et al. 2009;
Laursen et al. 2011), the guideline for schizophrenia and
other psychotic disorders (NICE 2009) states that a high
level of somatic health care is often needed. This guideline
stresses the importance of early detection of cardio-vas-
cular risk factors, also referred to as the ‘metabolic syn-
drome’. It recommends that regular somatic screening is
done that covers family disease history and personal risks
on diabetes mellitus, hypertension, cardiovascular diseases,
cancer, smoking, diet, activity and other metabolic risk
factors. Indicated treatment should start as early as possi-
ble. It also recommends that general practitioners (GPs)
and mental healthcare professionals work closely together
to meet the somatic needs of patients with psychosis, who
often do not communicate their somatic complaints ade-
quately (De Hert et al. 2011b, c).
Studies have found divergent results with regard to
somatic Health Care use (HCu) by individuals with NAPD
and other forms of SMI. They typically focused on specific
types of HCu. For instance, Carr et al. (2003) found higher
patterns of overall psychiatric and non-psychiatric health
service use for patients with psychotic disorders in Aus-
tralia compared to patients with nonpsychotic disorders.
Dickerson et al. (2003) reported mixed findings on HCu,
such as higher medical care use and lower dental care use,
among outpatients with SMI in Baltimore, Maryland
(USA) compared to matched subsets of individuals from
the general population. Oud et al. (2010) found that
patients with NAPD had more frequent GP consultations
and home visits in general primary care in The Nether-
lands, compared to patients with other mental disorders and
patients without mental disorders. Studies have also
reported similar or lower rates of specialist HCu for
patients with psychoses or SMI (Laursen et al. 2009). Other
research suggests underutilization in HCu, especially in
preventive care and primary care, compared to controls
with and without another psychiatric diagnosis (Druss et al.
2002; Hippisley-Cox et al. 2007; Folsom et al. 2002;
Roberts et al. 2007) and in specialist services (Salsberry
et al. 2005; Young and Foster 2000; Nasrallah et al. 2006).
It should be noted that higher or similar levels of HCu
do not preclude serious undertreatment. Domino et al.
(2014) found that the quality of care metrics was gener-
ally lower among patients with depression or
schizophrenia than for other patients in an adult Medicaid
population with two or more out of eight chronic condi-
tions (asthma, chronic obstructive pulmonary disease,
diabetes, hypertension, hyperlipidemia, seizure disorder,
depression, or schizophrenia). In addition, high utilization
of emergency rooms for patients with SMI and a higher
risk of hospitalization due to ambulatory care-sensitive
medical conditions may point to poor access or inefficient
use of the primary health care system (Salsberry et al.
2005; Muck-Jorgensen et al. 2000; Li et al. 2008). In fact
some studies point to higher levels of undertreatment
especially for the most vulnerable subsets of patients such
as older or homeless persons with SMI (Young and Foster
2000; Folsom et al. 2002; McCarthy and Blow 2004).
Parity in the access to care seems to be hindered by a
mixture of patient, provider treatment and system factors.
For instance, patients may choose not to seek help for
physical problems due to symptoms of SMI, there is a
focus on mental rather than physical health problems in
mental health care, people with mental disorders are
sometimes stigmatized by physicians, and the funding of
somatic care throws up financial barriers (De Hert et al.
2011b).
Few large studies so far have compared patients with
NAPD to healthy controls and patients with other psychi-
atric disorders across the full spectrum of HCu (i.e., general
and specialist somatic care). Yet, they are important in
monitoring possible undertreatment and finding its corre-
lates. Accordingly, the aim of the current study was to
examine whether patients with NAPD have a lower
somatic HCu level compared to controls without NAPD.
We performed a retrospective observational study using
linked registry and health plan data to compare HCu by
patients with NAPD to HCu by non-psychiatric matched
controls. For a sound interpretation, we also included
patients with an anxiety, depressive or bipolar disorder as
psychiatric references. Patients with these other psychiatric
disorders are also at increased risk of premature natural
death (Harris and Barraclough 1998; Laan et al. 2011), but
may be less socially marginalized and may show less
cognitive impairment, which relates to lower HCu (Carr
et al. 2003). Consequently, the HCu of these other patient
groups (also compared to controls) may more clearly point
out the somatic care needs of patients with NAPD. By
comparing NAPD patients to controls from the general
population as well as other patient groups, we investigated
whether undertreatment for somatic problems of psychosis
patients was present and what factors determined this
undertreatment.




Since 1999, the Psychiatric Case Registry for the Central
Netherlands (PCR-MN) has received anonymous infor-
mation on patient characteristics and mental health care
(MHC) of patients who use psychiatric services in the city
of Utrecht and surrounding municipalities. In 2010, the
area had over 760,000 inhabitants and formed a represen-
tative sample of 5 % of the Dutch population (Smeets et al.
2011). Under the Dutch system, health insurance is com-
pulsory for all residents. Data from PCR-MN were
anonymously linked to the Achmea Health Database
(AHD), which records payments for medical care made by
the largest insurance company in the region. This database
includes payments for drug prescriptions delivered by
community pharmacists, payments for GP consultations
and for Diagnostic and Treatment Protocols (DTPs, in
Dutch: ‘Diagnose Behandel Combinatie’) in all treatment
settings (e.g. hospital, emergency department, outpatient
clinic). A DTP is the insurance claim containing codes for
diagnosis and treatment by medical specialists. Each DTP
contains four codes: for a certain type of care, care demand,
diagnosis, and treatment followed. We used this informa-
tion to estimate HCu for physical disorders. Dutch privacy
law allows use of these data for scientific research under
strict conditions in relation to anonymity and storage, in
which case informed consent is not needed. The research
was approved by the institutional review board.
Patients and Data Extraction
Data were extracted for all 4770 adult patients (18 years)
with NAPD with least one care contact between January
2007 and December 2009 at Altrecht MHC, which is the
main mental health service in the Utrecht region. NAPD
was defined conform DSM-IV subgrouping (codes 295.10,
295.20, 295.30, 295.40, 295.60, 295.90, 295.70, 297.1,
297.30, 293.81, 293.82, 298.80, 298.90). Half of these
patients (2392) were insured with Achmea. This insurance
company serves for a relatively large number of insured
patients with lower social economic status, similar to
Medicaid in the USA. We extracted data from the AHD on
the HCu in the year before the last care contact at mental
health care service Altrecht in the period 2007–2009 (‘in-
dex date’). Controls without NAPD were randomly selec-
ted from the AHD and were personally matched: for each
individual patient six unique control persons with similar
birth year, gender, and ethnic group (Western vs. Non
Western) but without NAPD were selected from the AHD
(Table 1). We extracted the data on HCu by the controls
for the same year prior to the last care contact of the
matched patient with a psychiatric diagnosis. We followed
the same procedure for other groups with a psychiatric
diagnoses: bipolar disorder (N = 700), unipolar depression
(N = 5603), anxiety disorder (N = 1707). In the event of
psychiatric comorbidity, patients were categorized
according to their most severe disorder, which was NAPD,
bipolar depression, major depression and anxiety disorder,
respectively.
Table 1 Study population
Patients Matched controls
Total N = 10,402 N = 61,850
Gender N (%)
1. NAPD
Male 1438 (60.1) 8628 (60.1)
Total 2392 14,350
2. Bipolar
Male 284 (40.6) 1704 (40.6)
Total 700 4200
3. Unipolar
Male 1958 (34.9) 11,604 (35.1)
Total 5603 33,058
4. Anxiety
Male 659 (38.6) 3954 (38.6)
Total 1707 10,242
Age Mean (SD)
1. NAPD 47.8 (14.8) 47.5 (14.9)
2. Bipolar 51.6 (14.1) 51.2 (14.1)
3. Unipolar 46.2 (15.5) 46.1 (15.6)
4. Anxiety 42.2 (14.9) 42.0 (14.9)
Non-Western ethnic origin (%)
1. NAPD 21.2 21.2
2. Bipolar 6.0 6.0
3. Unipolar 29.4 30.6
4. Anxiety 21.3 21.3
Duration since earliest registered Mean (SD)
Psychiatric diagnosis
1. NAPD 5.2 (3.5) 5.2 (3.5)
2. Bipolar 5.1 (3.4) 5.1 (3.4)
3. Unipolar 3.0 (2.9) 3.0 (2.9)
4. Anxiety 2.3 (2.7) 2.3 (2.7)
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Analysis
Patients with a Psychiatric Diagnosis Versus
Controls
HCu by patients in the four mental health categories and by
their matched controls was estimated in terms of percent-
ages of patients with C1 somatic medication prescription,
C1 GP consultation, C1 somatic specialist consultation,
and at least one of these sources of somatic HCu. Using a
logistic regression model, we calculated the average mar-
ginal effect (AME; Williams 2012) and 95 %-confidence
interval (95 % CI) to test the difference in percentages of
somatic HCu between the groups of patients with a psy-
chiatric diagnosis and the controls without a psychiatric
diagnosis. We also differentiated the HCu in somatic dis-
ease category as diagnosed by the specialist (and registered
in the DTPs): lung diseases, cardio-vascular diseases,
cancer, diabetes or other physical disorders. Presence of a
specific prescribed drug (e.g., antiarrhythmics, blood glu-
cose lowering drug) and/or a specific diagnosis in a
registered DTP (e.g. ischemic heart disease, diabetic
retinopathy) was regarded as presence of somatic care for
these physical disorders. Also the average costs reimbursed
for the utilization of somatic health services were estimated
and the difference (Delta) between patients and controls
was tested using a t test. Appendix 1 lists somatic diag-
noses and information on the Anatomical Therapeutic
Chemical classification system used to specify somatic
disease categories of HCu.
Patients with NAPD versus Controls: Determinants
of the Difference in HCu
We analyzed the effects of age and duration since earliest
registered psychiatric diagnosis and other covariates (gen-
der, ethnic minority status, psychiatric comorbidity) on the
difference in somatic HCu between patients with NAPD
and their matched controls in a multiple logistic regression
model. A significant {covariate 9 ‘patient vs. control’}
interaction indicates that the differences in HCu between
patients with NAPD and controls differs across levels of
the covariate. To facilitate comparison with other studies
on somatic HCu the calculations were also performed for a
smaller subset of patients with schizophrenia,
schizophreniform and schizoaffective disorder. For each
somatic HCu outcome parameter (medication, GP, DTP,
and ‘any HCu’) separately, the covariates and terms for
interaction were included in one separate multiple logistic
model. Finally, we analyzed the difference in somatic HCu
between patients with NAPD and controls specifically for
cardiovascular diseases and for diabetes.
Data management, record linkage and crude estimations




For patients with NAPD in our regional psychiatric case
register, 50 % were insured with Achmea during the year
prior to index date in 2006–2009. The Achmea insurance
rate was lower for the other psychiatric diagnostic groups:
36.1 % for bipolar disorder, 37.0 % for major depression
and 31.7 % for anxiety disorders. On average, included
patients were older than excluded patients without Achmea
database linkage (e.g., for NAPD: 47.8 vs. 43.7 years,
p\ 0.001). They also showed a longer period in care since
the first registration of their most severe mental health
diagnosis (i.e. the diagnosis used for categorization in this
study) in the PCR-MN (e.g., for NAPD: 5.2 vs. 3.6 years,
p\ 0.001).
Table 1 shows characteristics of the study population.
More than half of the patients with NAPD were diagnosed
with schizophrenia (59.0 %). Schizophreniform, schizoaf-
fective or delusional disorder were also common diagnoses
(14.6 %) and 26.4 % suffered from another NAPD, which
was often ‘‘psychotic disorder not otherwise specified’’.
Patients with a Psychiatric Diagnosis
versus Controls: HCu (Univariable)
No significant differences were found between patients
with NAPD and their matched controls in the percentages
of patients with at least one somatic medication prescrip-
tion or with at least one GP contact during the year prior to
the index date (somatic medication: 72.2 vs. 73.3 %; GP:
77.2 vs. 76.9 %, Table 2). Among patients with bipolar
disorder, unipolar depression or anxiety disorder we did
find significantly higher percentages of HCu compared to
their matched controls. The percentage of patients with
NAPD with specialist somatic treatment was even lower
compared to their controls (44.3 vs. 47.2 %). Percentages
of patients with bipolar, unipolar or anxiety disorders with
specialist somatic treatment were all higher compared to
their controls. The percentage of patients with NAPD with
any somatic HCu (medication and/or GP consultation and/
or specialist care) was slightly higher compared to controls
[87.3 vs. 85.1 %; AME 2.25 (0.80 to 3.71) p = 0.002]. For
patients with bipolar disorder, unipolar depression or anx-
iety disorder, these percentages were markedly higher than
for controls, which resulted in large, statistically significant
marginal effects (Table 2).
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Slightly more pronounced results were found when the
analysis for NAPD was restricted to schizophrenia,
schizophreniform and schizoaffective disorder (no
table included): e.g., the differences for GP contacts and
specialist care became larger compared to controls [71.96
vs. 75.47 %; AME 3.52 (-5.85 to -1.18) p\ 0.01] and
[39.76 vs. 45.39 %; AME -5.61 (-8.19 to -3.05)
p\ 0.001], respectively.
Patients with a Psychiatric Diagnosis Versus
Controls: Associated Costs of HCu (Univariable)
Figure 1 presents reimbursements for somatic HCu in
number of euros per year. Obviously, the average difference
in costs for all insurance claims of patients with NAPD
compared to their matched controls (Difference, Delta
D = €180.30) was lower than the average differences for the
other groups with a psychiatric diagnosis compared to their
matched controls. Results were similar when we restricted
the analysis for NAPD to schizophrenia, schizophreniform
and schizoaffective disorder [D = €-94.40 (-327.0 to
137.1)].
For the patients with bipolar disorder, this average dif-
ference in costs compared to their matched controls was
higher than the difference for the patients with NAPD
[D = €373.30 (-30.8 to 777.5) vs. D = €180.30 (-20.9 to
381.6)], but lower than the difference in costs among the
patients with depression [D = €910.00 (778.2 to 1041.8)]
and anxiety [D = €646.50 (430.6 to 862.4)]. Compared to
controls, patients with NAPD did not have significantly
higher reimbursements for claims for somatic medication
prescriptions [D = €53.40 (-23.6 to 130.5)] or specialist
treatment [(D = €90.80 (-77.3 to 259.1)].
Patients with a Psychiatric Diagnosis Versus
Controls: HCu Associated with Treatment
by Medical Specialists, Classified into Somatic
Diagnosis Categories (Univariable)
Table 3 shows the HCu delivered by medical specialists, as
shown in Table 2, but now broken down into somatic
diagnostic categories. The relatively low HCu of specialist
care by patients with NAPD is mainly explained by lower
HCu compared to controls in the following categories:
cardiovascular diseases [7.98 vs. 8.51 %; AME = -0.52
(-1.7 to 0.65)], oncology [4.77 vs. 5.66 %; AME = -0.89
(-1.82 to 0.04)] and diabetes [2.88 vs. 3.23 %;
AME = -0.35 (-1.08 to 0.38)]. For respiratory disorders,
a significantly higher percentage of NAPD patients with a
HCu compared to controls was found [5.06 vs. 3.45 %,
AME = 1.61 (0.68 to 2.53) p\ 0.01]. Other diagnosis
groups had significantly higher percentages HCu for res-
piratory disorders compared to controls (AMEs ranged
from 2.96 to 3.80), but also for other categories of somatic
disorders. Particularly patients with unipolar depression or
an anxiety disorder had a higher HCu for cardiovascular
diseases compared to their controls [AME = 4.92 (3.99 to
5.85) and 5.95 (4.30 to 7.59) respectively]. We found
Table 2 Somatic Health Care utilization of patients with NAPD, bipolar disorder, unipolar disorder and anxiety, each group compared to
matched controls; percentage, average marginal effect (AME)a and (95 %-confidence interval)




% C1 contacts with general
practitioner
% C1 DTP with somatic
diagnosis
% with any somatic
HCu
Patients Controls Patients Controls Patients Controls Patients Controls




































DTP diagnostic treatment protocol
a Difference in percentages of HCu between patients and controls computed as average marginal effect
* p\ 0.05, ** p\ 0.01, *** p\ 0.001
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similar results when we restricted the analysis for NAPD to
schizophrenia, schizophreniform and schizoaffective dis-
order (data available on request).
Patients with NAPD Versus Controls: Determinants
of the Difference in HCu (Multiple)
The difference in somatic HCu between patients with
NAPD and their matched controls differed significantly by
strata defined on the basis of age and duration since earliest
registration of NAPD in the PCR-MN (3 age cate-
gories 9 3 duration categories give a factor with nine
levels) (Tables 4, 5). Estimates were adjusted for gender,
ethnic origin, presence of comorbid depressive and/or
personality disorder and/or comorbid substance abuse/de-
pendence. The effect of the interaction with df = 8 for
each indicator of HCu refers to the differences between the
nine different average marginal effects per stratum,
simultaneously tested as one cluster of terms for the 1st
order interaction between the above mentioned factor and
Fig. 1 Reimbursed costs associated with Health Care utilization for
somatic disorders (medication, GP consults, and specialist care);
difference in mean costs (Delta) between patients with NAPD and
matched controls and difference in mean costs between patients with
other psychiatric diagnoses and matched controls [95 % Confidence
Interval]
Table 3 Somatic Health Care utilization of patients with NAPD, bipolar disorder, unipolar disorder and anxiety compared to matched controls;
percentage, average marginal effect (AME)a and [95 %-confidence interval]
Diagnosis % C1 DTP with somatic
diagnosis: Respiratory
disorders




% C1 DTP with
somatic diagnosis:
Oncology
% C1 DTP with
somatic diagnosis:
Diabetes
% C1 DTP with somatic
diagnosis: Other physical
disorders
Patients Controls Patients Controls Patients Controls Patients Controls Patients Controls









AME = -2.36 *
(-4.47 to -0.25)

































DTP diagnostic treatment protocol
a Difference in percentages of HCu between patients and controls computed as average marginal effect
* p\ 0.05, ** p\ 0.01, *** p\ 0.001
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‘patient versus control’ in one analysis step. The highly
significant test for interaction (p\ 0.001) does not point to
undertreatment in one specific subgroup of patients com-
pared to their matched controls, in the first place, but does
show clear differences between categories defined on the
basis of age and illness duration. The effect for the indi-
cator ‘any somatic HCu’ presented in Table 5 was a 3.64
percentage point difference (-3.07 to 10.34) for those
under 40 and for shorter durations (\2 years), and was
substantially and significantly lower (i.e. larger in the
negative direction) for older patients C 60 years) with a
longer mental health care duration ([5 years): a -10.99
percentage point difference (-17.02 to -4.97) p\ 0.001.
Similar trends by age and the duration in mental health
care were found and significant tests for interaction were
obtained for the other indicators of HCu: ‘somatic medi-
cation’, ‘GP consultations’ and ‘medical specialist treat-
ment’ separately. Again similar trends were found when we
restricted these analyses to schizophrenia, schizophreni-
form and schizoaffective disorder (data available on
request).
Male gender, presence of comorbid depressive disorder,
and comorbid alcohol abuse/dependence were associated
with a higher somatic HCu among patients with NAPD
versus their controls—percentages, AMEs and p values for
interaction are respectively: 85.21 versus 80.57 %;
AME = 5.14 (2.56 to 7.73) p\ 0.001; 92.99 versus
85.49 %; AME = 6.80 (4.14 to 9.47) p =\ 0.001; 92.10
versus 85.57 %; AME = 8.60 (4.65 to 12.54) p\ 0.001.
The percentage of patients with prescribed somatic medi-
cation tended to be lower for patients with NAPD versus
matched controls (66.86 vs. 72.42 %) when there was a
comorbid diagnosis of drug abuse/dependence but this
difference tested as AME was non-significant.
Patients with NAPD vs. Controls: Determinants
of Difference in HCu for Cardiovascular Disorders
and Diabetes (Multiple)
The somatic HCu related to cardiovascular disorders (i.e.
having received cardiovascular medication and/or special-
ist treatment with cardiovascular diagnosis) among patients
with NAPD compared to their matched controls was lower
for older patients (C60 years) with longer durations of their
disorder ([5 years) (AME -23.95 [-31.17 to -16.73],
p\ 0.001). Higher AMEs were found for those patients
under 40 with shorter durations (\2 years) compared to
controls [AME 3.42 (-0.76 to 7.60)]; p value for 1st order
interaction of age and duration\0.001).
Effects of age and duration on the differences in per-
centages of somatic HCu related to diabetes showed a
similar pattern (p value for 1st order interaction = 0.0020).
Table 4 Differences in Health Care utilization for somatic disorders of patients with NAPD compared to matched controls by stratum of age and
duration since earliest date of registered diagnosis; percentage, average marginal effect (AME)a and 95 % confidence interval
Diagnosis Number of patients/
number of controls
% C1 medication prescriptions
Patients with NAPD versus controls
% C1 contacts with GP
Patients with NAPD versus controls
% % AME 95 % CI % % AME 95 % CI
Age & duration
\40 years
\2 years 223/1320 59.1 65.5 -6.32 -14.55 to 1.90 84.9 73.5 11.55*** 5.38 to 17.72
2–5 222/1314 64.5 65.2 -0.63 -8.93 to 7.67 74.3 71.0 3.36 -4.31 to 11.02
C5 384/2304 61.0 66.7 -5.95 -13.21 to 1.31 71.6 73.3 -1.84 -8.80 to 5.11
40–60 years
\2 years 203/1224 69.3 75.5 -6.24 -14.17 to 1.68 86.3 77.6 8.72** 2.75 to 14.69
2–5 294/1770 66.1 76.0 -9.80** -16.73 to -2.87 73.0 77.0 -3.95 -10.55 to 2.65
C5 567/3390 67.8 75.0 -7.31* -13.05 to -1.57 73.3 77.8 -4.60 -10.20 to 0.99
[60 years
\2 years 154/934 80.6 87.3 -5.87 -12.56 to 0.82 86.8 84.9 1.71 -4.00 to 7.43
2–5 123/750 69.4 86.2 -15.22** -23.85 to -6.60 77.4 82.3 -4.50 -12.40 to 3.39
C5 222/1344 65.9 86.3 -19.05*** -25.97 to -12.12 70.4 84.0 -12.77*** -19.53 to -6.01
Effect of interaction between stratum (age &
duration) and patient versus control (df = 8)
p\ 0.001 p\ 0.001
Adjusted for gender, ethnic minority, depression, personality disorder, alcohol and drug abuse/dependence
a Difference in percentages of HCu between patients and controls computed as average marginal effect
* p\ 0.05, ** p\ 0.01, *** p\ 0.001
656 Adm Policy Ment Health (2016) 43:650–662
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Compared to their age-matched controls, patients over the
age of 60 with a longer duration of their disorder received
less anti-diabetic medication and/or less specialist treat-
ment for diabetes [AME = -2.76 (-7.98 to 2.45)]
whereas higher AMEs were found for younger patients (see
Appendix 2).
Discussion
In this study, we found a slightly higher somatic HCu and
associated costs among patients with NAPD compared to
their matched controls. However, this difference in HCu
was lower than the difference found for other groups with a
psychiatric diagnosis, especially a depressive or an anxiety
disorder. In addition, the somatic HCu of patients with
NAPD was lower compared to their matched controls when
the analysis was restricted to treatments delivered by a
medical specialist. There was a clear and significant trend
toward a negative difference in HCu with increasing age
and longer duration since registered diagnosis.
Younger patients with NAPD who spend less time in
mental health care had a higher percentage of contacts with
the GP compared to controls, but not for specialist care.
The comparatively low HCu among patients with NAPD at
higher ages was especially noteworthy for cardiovascular
diseases and diabetes. Our findings contrast with the poorer
health conditions and substantially higher risk of cardio-
vascular and other early natural death causes of patients
with NAPD, as reported earlier. This study therefore
strongly suggests underutilization of somatic HC by
patients with NAPD.
Comparison with Other Studies
Our results are consistent with studies in various countries
showing that patients with SMI or a psychotic disorder
make less overall use of somatic health care than other
patients with a psychiatric diagnosis and have a lower HCu
of specialist services than patients in the general popula-
tion. Our findings contrast with the studies from Dickerson
et al. (2003) and Carr et al. (2003) who found higher HCu
for patients with schizophrenia than for the general popu-
lation. A possible explanation is that these studies con-
cerned a selection of patients currently receiving outpatient
care that may promote attention to physical health.
In our study especially older patients with a longer
duration in mental health care had a lower HCu which is
also consistent with other research. Notably the research by
Folsom et al. (2002) indicates that middle-aged and older
homeless people with schizophrenia in California receive
less primary and preventive health care and are treated for
Table 5 Differences in Health Care utilization for somatic disorders of patients with NAPD compared to matched controls by stratum of age and





% C1 DTP with somatic diagnosis
Patients with NAPD versus controls
% with any somatic HCu
Patients with NAPD versus controls
% % Average marginal
effect





\2 years 223/1320 37.4 38.6 -1.15 -8.89 to 6.59 85.2 81.7 3.64 -3.07 to 10.34
2–5 222/1314 38.1 38.2 -0.02 -7.90 to 7.86 85.6 81.2 4.54 -2.25 to 11.33
C5 384/2304 34.4 37.8 -3.39 -9.74 to 2.97 80.5 81.9 -1.53 -8.43 to 5.35
40–60 years
\2 years 203/1224 45.1 47.9 -2.80 -11.01 to 5.41 87.9 86.1 1.18 -4.29 to 7.91
2–5 294/1770 33.2 47.4 -14.27*** -20.87 to -7.67 80.6 86.5 -5.79 -12.1 to 0.55
C5 567/3390 36.9 46.6 -9.71** -15.18 to -4.24 81.6 86.1 -4.68 -10.07 to 0.71
[60 years
\2 years 154/934 58.4 66.2 -7.60 -16.20 to 0.98 91.6 92.5 -0.70 -5.49 to 4.09
2–5 123/750 58.9 65.7 -6.66 -16.27 to 2.94 88.5 91.2 -2.23 -8.44 to 3.98
C5 222/1344 47.5 64.2 -16.61*** -24.10 to -9.12 80.6 93.1 -10.99*** -17.02 to -4.97
Effect of interaction between
stratum (age & duration) and
patient versus control (df = 8)
p = 0.0047 p\ 0.001
Adjusted for gender, ethnic minority, depression, personality disorder, alcohol and drug abuse/dependence
a Difference in percentages of HCu between patients and controls computed as average marginal effect
* p\ 0.05, ** p\ 0.01, *** p\ 0.001
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fewer chronic medical problems than a comparison group
with major depression. In the Dutch study by Oud et al.
(2010) patients with psychosis had more frequent GP
consultations compared to other primary care patients, but
similar or lower rates of GP contacts were found, especially
among the elderly patients with psychosis, for diabetes,
cardiovascular and respiratory diseases. This study was
restricted to those with at least one GP consultation during
the study period, which may imply that psychosis patients
with comparatively high levels of HCu were slightly
overrepresented. A higher level of undertreatment at higher
ages has also been observed for cardiovascular procedures
after myocardial infarction in patients with SMI, especially
those with schizophrenia (Young and Foster 2000). Among
142,055 Veterans Affairs patients with SMI, McCarthy and
Blow (2004) found that patients over 65 were substantially
more negatively affected by distance barriers to use non-
psychiatric somatic care. Furthermore, in the study of
Laursen et al. (2011) in Denmark, slightly higher rates of
heart disease admissions were found among patients with
schizophrenia and bipolar disorder, alongside an excess of
cardiac mortality. Consistent with our results, they found
an interaction between lower admission rates and higher
ages. However our findings contrast with the study from
Cradock-O’Leary et al. (2002) using data from the
Department of Veterans Affairs. They found fewer medical
visits and the lowest rates of diagnosed pulmonary disease,
diabetes and hypertension among patients with a diagnosis
of schizophrenia or bipolar disorder compared with other
VA patients. In contrast to our findings, however, a slightly
higher number of medical care visits were found at higher
ages among those with schizophrenia while younger
patients with schizophrenia had an especially high risk of
not receiving general medical services. This need for
somatic HCu among the partly institutionalized elderly
with SMI may come to light more in a comprehensive
system of both medical and mental health care such as the
Department of Veterans Affairs.
Strengths and Limitations
Our study has several strengths. We reported HCu for a
large group of patients with NAPD, other groups with a
psychiatric diagnosis and their matched controls. We
examined several aspects of HCu (somatic medication
prescriptions, GP and somatic specialist consultations)
broken down into specific somatic diagnoses and associ-
ated costs. Objective data from insurance claims were used,
thus precluding the risk of recall bias. In addition, impor-
tant covariates—age, gender, psychiatric diagnosis, eth-
nicity and alcohol and drug dependency—were taken into
account. Therefore, this study can contribute to tracking
patient groups at high risk of undertreatment.
A number of limitations of the study needs to be addres-
sed. First, the analyses were based on insurance payments for
GP consultations and somatic health care treatments. No
information was available on the actual presence or severity
of somatic disorders, whether diagnosed and treated or not.
Second, the data specified the distribution of crude categories
of HCu (i.e. medication, GP or specialist care). Adminis-
trative database studies like this study can signal general
health problems that should be followed by further research.
Detailed information concerning duration of admissions and
outpatient care, use of specific cardiovascular procedures
and/or other preventive measures and degree of integration
of the care system could provide more insight into the nature
of the somatic underconsumption by patients with NAPD
and ways to improve this.
A third limitation is the cross-sectional study design,
which was restricted to patients in an arbitrary year prior to
the date of the last mental health care contact in 2007-2009.
Selection of those who do relatively well and have survived
the high mortality risks during the early phases of their
treatment (‘healthy survivor’ effect) may lead to an under-
estimation of HCu (Oud et al. 2010; Laursen et al. 2009). In
addition, people who receive mental health care for a longer
periodmay have developed better self-management skills for
somatic problems that tie in closely with their experience in
managing their psychiatric disorder (Dixon et al. 2004).
However these considerations do not fully explain why HCu
by patients with NAPD is lower than that of other psychiatric
patient groups, who probably experienced similar survival
benefits and developed similar self-management skills.
A final limitation is that the aim of the study was to
examine whether patients with NAPD have lower levels of
somatic HCu compared to psychiatric and healthy controls,
but no explanation can be given for the outcomes based on
the present results. The in comparison with controls higher
percentages with at least one contact with the GP in
younger patients with a shorter illness duration since the
first registration of their diagnosis in the PCR-MN may
point to the important function of the GP in the early
diagnostic phases of a psychotic disorder. The observed
trend towards lower percentages of contacts with the GP
and somatic specialists (compared to age-matched con-
trols) among the elderly NAPD patients with longer illness
duration may be partly a result of the aforementioned
selection of relatively fit people at higher ages (‘healthy
survivor’ effect). However an additional explanation could
be that finding your way to the somatic health care system
is extra difficult for the most vulnerable patients (Hert,
Cohen, et al. 2011b; Thornicroft et al. 2007). Doctors
prescribing antipsychotics do not always accurately moni-
tor somatic complications (Okkels et al. 2013), they may
find this too stressful for patients with psychosis (Cahn
et al. 2008). Reluctance to address patients and distance
658 Adm Policy Ment Health (2016) 43:650–662
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barriers as found by McCarthy and Blow (2004) could
promote somatic undertreatment particularly in older
patients. Differences in the distribution of NAPD sub-di-
agnoses among the age categories is a less likely expla-
nation, as similar results were found when the analysis for
Tables 4 and 5 was restricted to schizophrenia,
schizophreniform and schizoaffective disorder.
Conclusions
Our data indicate undertreatment for physical disorders
among patients with NAPD particularly for older patients
with NAPD. This implies that the national context with
compulsory insurance for all inhabitants in the Netherlands
does not lead to parity in HCu. The lower HCu and lower
costs incurred for medical specialist care among persons
with NAPD are reasons for concern. Our data suggest that
we have not yet achieved the goals of lowering the cardio-
vascular risk factors as formulated in the international
guidelines on psychosis and schizophrenia. Improving
awareness of the risks of undertreatment among health
professionals and the public is an important starting point
in bridging the health care gap between patients with SMI
and the general population (Thornicroft et al. 2007; Ahire
et al. 2013). We suggest a more assertive approach in the
way somatic health care is delivered to these patients. By
enhancing early detection of risk factors for diseases such
as hypertension, weight gain and elevated cholesterol, it
may be possible to decrease the rates of early deaths in
patients with NAPD. Integration of medical and psychiatric
care and preventive interventions may also result in
improved quality of medical care (Nasrallah et al. 2006;
Druss et al. 2001; Cahn et al. 2008; De Hert et al. 2011b,
c). Further studies on somatic health care to patients with
NAPD - from the appearance of initial symptoms to help-
seeking, assessment, start of treatment and follow-up—are
needed to find entry points for improving the match
between needs and delivery of treatment.
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Appendix 1
Information on the diagnosis by medical specialists and
prescribed medications that were decisive for inclusion of
patients in the categories respiratory disorders, cardiovas-
cular disorders, oncology, diabetes or other physical
disorders.
Respiratory disorders
Included are all respiratory disorders diagnosed by a
medical lung specialist [airway diseases such as asthma,
emphysema, bronchiectasis and chronic bronchitis, lung
tissue diseases such as pulmonary fibrosis and sarcoidosis,
unspecified problems (like chest pain, dyspnea, cough) and
other diagnoses (such as hyperventilation syndrome, nico-
tine addiction)] and medications prescribed by specialists
or GPs for respiratory disorders (WHO site http://www.
whocc.no/, selection of all ATC codes starting with ‘R’).
Cardiovascular disorders
Included are all cardiovascular diseases diagnosed by a
cardiologist (coronary artery disease, heart attack, abnor-
mal heart rhythms or arrhythmias, heart failure, heart valve
disease, congenital heart disease, vascular diseases) and
medications prescribed by specialists or GPs for cardio-
vascular disorders (WHO site http://www.whocc.no/,
selection of all ATC codes starting with ‘C’).
Diabetes
Included are the diagnosis of diabetes mellitus (I and II)
diagnosed by a medical specialist and medications pre-
scribed by specialists or GPs for diabetes (WHO site http://
www.whocc.no/, selection of all ATC codes starting with
‘A10’).
Oncology
Included are all oncological diagnoses by a medical spe-
cialist; breast cancer, skin cancer, lung cancer, colon cancer,
prostate cancer, lymphoma and all other ([100 types of)
cancers. No extra medication search in the health database
was needed since patients never receive cancer medication
without a registered diagnosis by a medical oncologist or
receive this medication prescribed by their GP.
Other
All other somatic diagnoses by a medical specialist not
included above.
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